Observation on the minimum effective concentration of ropivacaine for intermuscular brachial plexus block after shoulder arthroscopy under ultrasound guidance

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047978

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-07-20

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder joint injury

Interventions

Ropivacaine group:Ropivacaine brachial plexus block

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18-60 years old; 2. ASA I-II grade; 3. The operation time does not exceed 120 minutes.

Exclusion criteria

Exclusion criteria: 1. Revision of shoulder joint surgery; 2. Severe bleeding disorder; 3. Block site infection, diabetes or peripheral neuropathy, limb neurological dysfunction; 4. Study drug allergy; 5. Body mass index (BMI) > 35kg/m2; 6. Mental disorders and communication difficulties.

Design outcomes

Primary

Measure	Time frame
VAS scores at rest;VAS score when patients are active;	—

Secondary

Measure	Time frame
Perioperative opioid consumption;Length of operation;Laryngeal mask removal time;	—

Countries

China

Contacts

Public ContactXu Cheng

The Sixth People's Hospital Affiliated to Shanghai Jiaotong University

xucheng303@163.com+86 15102139984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026